Anti-Lysophosphatidic acid [B3]

Absolute Antibody

Anti-Lysophosphatidic acid [B3]

9

This antibody binds lysophosphatidic acid (LPA), which is a bioactive lipid mediating multiple cellular responses including proliferation, differentiation, angiogenesis, motility, and protection from apoptosis in a variety of cell types. LPA is involved i

The binding characterization of this antibody for different isoforms of LPA was done using ELISA. The original antibody binds LPA with a very high binding affinity of Kd= 1.4 pM. This antibody is capable of recognizing all the isoforms of LPS (12:0 LPA; 14:0 LPA; 16:0 LPA; 18:1 LPA; 18:2 LPA and 20:4 LPA). This antibody was reported to have an inhibitory effect on the LPA-stimulated migration of renal cell carcinoma (Caki-1) cells and also inhibit the release of pro-tumorigenic cytokines from tumor cells. This antibody could also inhibit tumor angiogenesis in vivo. In an in vitro mouse model of metastasis this antibody reduced tumor progression (US8604172). This antibody LPA and prevents it from interacting with its complement of receptors, and blocks LPAs effects on the neuronal differentiation of human neural stem/progenitor cells, demonstrating its specificity toward LPA signaling. When administered systemically to mice subjected to SCI, B3 substantially reduced glial inflammation and neuronal death (PMID: 22819724). Blocking LPA signaling with the this antibody B3/Lpathomab is neuroprotective in the mouse spinal cord following injury (PMID: 24576351).

ELISA, Other Application

Research Use Only

Monoclonal

B3

Rabbit

IgG

Other Species

-20°C,2°C to 8°C

12352203